Decibel Therapeutics announced a partnership with Invitae, to launch AmplifyTM, a no-charge genetic testing program to screen for the genetic cause of congenital hearing loss in children diagnosed with auditory neuropathy. AmplifyTM is available to individuals who meet the following criteria: Absent or highly abnormal Auditory Brainstem Response (ABR) in both ears; Presence of Distortion Product Otoacoustic Emissions (DPOAE) in at least three frequencies in at least one ear; Less than five years of age.
Decibel Therapeutics, Inc.
Equities
DBTX
US24343R1068
Biotechnology & Medical Research
1st Jan change | Capi. | |
---|---|---|
+25.83% | 4.66TCr | |
+45.38% | 4.17TCr | |
+0.69% | 4.12TCr | |
+30.52% | 3.24TCr | |
+22.30% | 2.82TCr | |
-6.35% | 2.81TCr | |
+49.25% | 1.45TCr | |
+49.18% | 1.37TCr | |
+3.45% | 1.22TCr |